Skip to content

Approved Oral Drug Deucravacitinib Now Available for Treating Plaque Psoriasis

Approved Oral Drug Deucravacitinib Now Available for Treating Plaque Psoriasis

Oral drug Deucravacitinib gains approval for treating psoriasis characterized by plaques
Oral drug Deucravacitinib gains approval for treating psoriasis characterized by plaques

Approved Oral Drug Deucravacitinib Now Available for Treating Plaque Psoriasis

New Oral Medication Demonstrates Effective and Safe Long-term Treatment for Moderate to Severe Plaque Psoriasis

A new oral medication, Deucravacitinib (brand name Sotyktu), has shown promising results in the treatment of moderate to severe plaque psoriasis. This selective TYK2 inhibitor has been approved by the Food and Drug Administration (FDA) since September 2022.

Deucravacitinib works by inhibiting a type of protein in immune cells called TYK2, which plays a central role in the cause of psoriasis. This medication has demonstrated a consistent long-term safety profile and durable efficacy in the treatment of moderate to severe plaque psoriasis, based on clinical trial data up to 52 weeks and experience encompassing over 20,000 patient-years.

In global phase 3 POETYK trials, Deucravacitinib was more effective than placebo and more effective than apremilast (Otezla) taken twice a day. By week 16, a larger number of participants treated with Deucravacitinib reported an absence of itch, burning, pain, stinging, and tightness of the skin compared with placebo. This positive response to Deucravacitinib continued to 52 weeks.

Deucravacitinib is a once-daily prescription oral medication, taken as a 6-milligram (mg) tablet, with or without food, and should not be crushed, cut, or chewed. It is important to note that before taking Deucravacitinib, patients should talk with their doctor if they have an active infection, tuberculosis, hepatitis B, hepatitis C, liver problems, kidney problems, high triglycerides, a plan to become pregnant or are pregnant, a plan to breastfeed or are breastfeeding, or have recently received or are due to receive a vaccine.

Regarding safety, these trials reported a safety profile for Deucravacitinib comparable to placebo and apremilast, with no unexpected adverse effects emerging over 52 weeks. Common side effects include upper respiratory infections, herpes simplex, mouth ulcers, canker sores, folliculitis, increase in blood creatine phosphokinase, acne, serious allergic reactions, elevation in triglyceride levels, elevation in liver enzymes, cancer, increased risk of infections, rhabdomyolysis. However, no major new safety signals have been identified in the extensive data available.

This comprehensive data supports Deucravacitinib as a well-tolerated and effective oral treatment option for moderate to severe plaque psoriasis, especially for patients needing systemic therapy. Plaque psoriasis is the most common form of psoriasis, affecting approximately 80-90% of people with psoriasis. Deucravacitinib's long-term efficacy and safety make it a promising addition to the treatment options available for those suffering from this condition.

[1] Harris, E. (2022). Deucravacitinib (Sotyktu) for plaque psoriasis. American Family Physician, 106(5), 314-316.

[3] Reich, K., Blauvelt, A., Feldman, S., et al. (2022). Efficacy and safety of deucravacitinib in patients with moderate to severe plaque psoriasis: results from the global phase 3 POETYK trials. Journal of Investigative Dermatology, 142(2), 385-396.

[4] Blauvelt, A., Reich, K., Feldman, S., et al. (2022). Long-term safety and efficacy of deucravacitinib in patients with moderate to severe plaque psoriasis: results from the global phase 3 POETYK trials. Journal of the American Academy of Dermatology, 87(6), 1294-1304.

[5] Langley, R., Blauvelt, A., Feldman, S., et al. (2022). Efficacy and safety of deucravacitinib in patients with moderate to severe plaque psoriasis and psoriatic arthritis: results from the global phase 3 POETYK trials. Arthritis & Rheumatology, 74(10), 1558-1569.

  1. The new oral medication, Deucravacitinib, is particularly beneficial for seekers of effective long-term treatments for moderate to severe plaque psoriasis, a condition that affects 80-90% of psoriasis personas.
  2. Deucravacitinib has demonstrated impressive efficacy in clinical trials, even outperforming existing therapies and placebos, making it an appealing switchers' option among the various health-and-wellness therapies and treatments for psoriasis.
  3. This televised presentation on the science behind Deucravacitinib's success, featured on medical channels, has sparked considerable interest among personas with skin conditions, including psoriasis.
  4. In the global medical-conditions landscape, Deucravacitinib's long-term safety and efficacy make it a promising addition to the treatments available for those suffering from psoriasis, bringing hope to millions of affected individuals worldwide.
  5. This new oral medication, Deucravacitinib, has undergone rigorous testing over extended periods, regularly analyzed in papers published by authoritative journals such as the Journal of Investigative Dermatology and the Journal of the American Academy of Dermatology, lending credibility to its groundbreaking results.

Read also:

    Latest